Q4 2023 Coloplast A/S Earnings Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Coloplast Full Year 2022-2023 Earnings Release Conference Call. (Operator Instructions)
I would now like to turn the conference over to Kristian Villumsen, President and CEO. Please go ahead.
/-&
Thank you, operator. Good morning, and welcome to our full year '22-'23 conference call. I'm Kristian Villumsen, the CEO of Coloplast, and I'm joined by our CFO, Anders Lonning-Skovgaard, and our Investor Relations team. We will start with a short presentation by Anders and myself and then open up for questions as we usually do. Could I ask you all to please turn to Slide #3.
We delivered 8% organic growth and a reported EBIT margin before special items of 28% for the '22-'23 financial year. Return on invested capital after tax and before special items was 17%, reflecting impact from the Atos Medical and Kerecis acquisitions. Now fourth quarter, we delivered organic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |